BioRestorative Therapies/$BRTX
1D1W1MYTD1Y5YMAX
Capital at risk
About BioRestorative Therapies
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
- Ticker
- $BRTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 14
- Headquarters
- Melville, United States
- Website
- www.biorestorative.com
BRTX Metrics
BasicAdvanced
$3.4M
-
-$19.51
0.74
-
Price and volume
Market cap
$3.4M
Beta
0.74
52-week high
$3.23
52-week low
$2.55
Financial strength
Current ratio
2.353
Quick ratio
2.233
Total debt to equity
0.01
Profitability
EBITDA (TTM)
-14.015
Gross margin (TTM)
92.09%
Net profit margin (TTM)
-3,089.55%
Operating margin (TTM)
-3,974.66%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-118.81%
Return on equity (TTM)
-241.14%
Valuation
Price to revenue (TTM)
4.26
Price to book
1.13
Price to tangible book (TTM)
1.36
Price to free cash flow (TTM)
-0.128
Free cash flow yield (TTM)
-780.40%
Free cash flow per share (TTM)
-20.991
Growth
Revenue change (TTM)
-8.47%
Earnings per share change (TTM)
-34.00%
3-year revenue growth (CAGR)
38.36%
10-year revenue growth (CAGR)
-2.33%
3-year earnings per share growth (CAGR)
-38.77%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.